Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triflupromazine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Intravenous
01
Overview
Triflupromazine is an antipsychotic medication of the phenothiazine class. It acts primarily as a dopamine receptor D1 and dopamine receptor D2 antagonist, reducing abnormal dopamine activity in the brain. This mechanism underlies its use in treating serious mental and emotional disorders such as schizophrenia and other psychotic disorders. Triflupromazine is also used to control violent behavior during acute psychotic episodes, severe nausea and vomiting, severe hiccups, and moderate to severe pain in some hospitalized patients. Its antiemetic effect is mainly due to blockade of dopamine receptor D2 in the chemoreceptor trigger zone (CTZ) and vomiting center. Additionally, it antagonizes muscarinic acetylcholine receptor M1 and muscarinic acetylcholine receptor M2 as well as serotonin receptor 5-HT2B[1][3][4][6].
- Brand names
- Vesprin
- Other names
- triflupromazineVesprin
02
Targets
HTR2B (5-Hydroxytryptamine Receptor 2B)M1 (Muscarinic acetylcholine receptor M1)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)CHRM2 (M2)
Beyond the preview
Go deeper on triflupromazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triflupromazine.